Given that stage IV carcinoids are uncommon, the therapeutic approaches for these tumors are largely extrapolated from the digestive NET, where Ki67 is included as part of parameters guiding treatment selection30,43,44. This evidence concerns the gene MKI67 and carcinoid tumor.